A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding

BMS-378806 is a recently discovered small molecule HIV-1 inhibitor that blocks viral entrance to cells. The compound exhibits potent inhibitory activity against a panel of R5-(virus using the CCR5 coreceptor), X4-(virus using the CXCR4 coreceptor), and R5/X4 HIV-1 laboratory and clinical isolates of the B subtype (median EC50 of 0.04 μM) in culture assays. BMS-378806 is selective for HIV-1 and inactive against HIV-2, SIV and a panel of other viruses, and exhibits no significant cytotoxicity in the 14 cell types tested (concentration for 50% reduction of cell growth, >225 μM). Mechanism of action studies demonstrated that BMS-378806 binds to gp120 and inhibits the interactions of the HIV-1 envelope protein to cellular CD4 receptors. Further confirmation that BMS-378806 targets the envelope in infected cells was obtained through the isolation of resistant variants and the mapping of resistance substitutions to the HIV-1 envelope. In particular, two substitutions, M426L and M475I, are situated in the CD4 binding pocket of gp120. Recombinant HIV-1 carrying these two substitutions demonstrated significantly reduced susceptibility to compound inhibition. BMS-378806 displays many favorable pharmacological traits, such as low protein binding, minimal human serum effect on anti-HIV-1 potency, good oral bioavailability in animal species, and a clean safety profile in initial animal toxicology studies. Together, the data show that BMS-378806 is a representative of a new class of HIV inhibitors that has the potential to become a valued addition to our current armamentarium of antiretroviral drugs.

[1]  C. Broder,et al.  Fusogenic mechanisms of enveloped-virus glycoproteins analyzed by a novel recombinant vaccinia virus-based assay quantitating cell fusion-dependent reporter gene activation , 1994, Journal of virology.

[2]  R. Doms,et al.  HIV-1 entry inhibitors: new targets, novel therapies. , 2003, Immunology letters.

[3]  The effects of high-dose recombinant soluble CD4 on human immunodeficiency virus type 1 viremia. , 1994, The Journal of infectious diseases.

[4]  Eric Hunter,et al.  Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry , 1998, Nature Medicine.

[5]  M. Boyd,et al.  New soluble-formazan assay for HIV-1 cytopathic effects: application to high-flux screening of synthetic and natural products for AIDS-antiviral activity. , 1989, Journal of the National Cancer Institute.

[6]  S. Marsters,et al.  Blocking of HIV-1 infectivity by a soluble, secreted form of the CD4 antigen. , 1987, Science.

[7]  R. Siliciano,et al.  A soluble CD4 protein selectively inhibits HIV replication and syncytium formation , 1988, Nature.

[8]  David E. Fisher.  Background on Bruno , 2000, Science.

[9]  D. Missé,et al.  Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes , 2003, Nature Biotechnology.

[10]  J. Mascola,et al.  Prevalence of genotypic and phenotypic resistance to anti-retroviral drugs in a cohort of therapy-naïve HIV-1 infected US military personnel , 2000, AIDS.

[11]  A. Trkola,et al.  Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults. , 2000, The Journal of infectious diseases.

[12]  J. Moore,et al.  An enzyme-linked immunosorbent assay for antibodies to the envelope glycoproteins of divergent strains of HIV-1. , 1989, AIDS.

[13]  A. Fauci,et al.  Current strategies in the treatment of HIV infection. , 2002, Advances in internal medicine.

[14]  R. Colonno,et al.  Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[15]  R. Koup,et al.  Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. , 1995, AIDS research and human retroviruses.

[16]  Elizabeth Connick,et al.  Antiretroviral-drug resistance among patients recently infected with HIV. , 2002, The New England journal of medicine.

[17]  S. Hammer,et al.  HIV fusion and its inhibition. , 2001, Antiviral research.

[18]  D. Ho,et al.  High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[19]  A. Trkola,et al.  Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG , 1995, Journal of virology.

[20]  P. S. Kim,et al.  HIV Entry and Its Inhibition , 1998, Cell.

[21]  V. Trouplin,et al.  Baseline Susceptibility of Primary Human Immunodeficiency Virus Type 1 to Entry Inhibitors , 2003, Journal of Virology.

[22]  J. Moore,et al.  AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor , 1998, Nature Medicine.

[23]  Hans Wolf,et al.  Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS , 1986, Cell.

[24]  S. Zolla-Pazner,et al.  Envelope glycoproteins from human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus can use human CCR5 as a coreceptor for viral entry and make direct CD4-dependent interactions with this chemokine receptor , 1997, Journal of virology.

[25]  B. Neustadt,et al.  Piperazine-based CCR5 antagonists as HIV-1 inhibitors. III: synthesis, antiviral and pharmacokinetic profiles of symmetrical heteroaryl carboxamides. , 2003, Bioorganic & medicinal chemistry letters.

[26]  Timothy P. Spicer,et al.  In Vitro Resistance Profile of the Human Immunodeficiency Virus Type 1 Protease Inhibitor BMS-232632 , 2000, Antimicrobial Agents and Chemotherapy.

[27]  J. McNamara,et al.  Recombinant CD4-IgG2 in human immunodeficiency virus type 1-infected children: phase 1/2 study. The Pediatric AIDS Clinical Trials Group Protocol 351 Study Team. , 2000, The Journal of infectious diseases.

[28]  G. Learn,et al.  HIV-1 Nomenclature Proposal , 2000, Science.

[29]  J. Montaner,et al.  Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. , 2003, The New England journal of medicine.

[30]  P. Volberding,et al.  The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. , 2002, AIDS research and human retroviruses.

[31]  G. Wormser.  AIDS and other manifestations of HIV infection , 2004 .

[32]  Gilcher Ro.  Human retroviruses and AIDS. , 1988 .

[33]  W A Hendrickson,et al.  Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates. , 2000, Structure.

[34]  J. Sodroski,et al.  Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody , 1998, Nature.

[35]  J. Sodroski,et al.  The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. , 1998, Science.

[36]  J. Moore,et al.  Adaptation of two primary human immunodeficiency virus type 1 isolates to growth in transformed T cell lines correlates with alterations in the responses of their envelope glycoproteins to soluble CD4. , 1993, AIDS research and human retroviruses.